Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
نویسندگان
چکیده
Bortezomib is an inhibitor of 26S proteasome, which is an effective treatment for multiple myeloma. The common adverse effects of bortezomib are asthenic conditions, gastrointestinal disturbances, and peripheral neuropathy. Here we describe a patient with dyspnea and general weakness because of complete atrioventricular block while receiving bortezomib. We immediately stopped bortezomib, and after inserting a permanent VDD pacemaker, the patients' symptoms disappeared.
منابع مشابه
Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity
Bortezomib is a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. Traditionally, bortezomib was thought to have little cardiovascular toxicity; however, there is increasing evidence that bortezomib can lead to cardiac complications including left ventricular dysfunction and atrioventricular block. We present the case of a 66-year-old man with multiple myeloma and per...
متن کاملMultiple Myeloma Presenting as Respiratory Stridor
Extramedullary plasmacytoma occurs in 18% of patients with multiple myeloma. Laryngeal involvement in multiple myeloma is rare, and only a few cases have been reported. We present a case of a 44-year-old women with multiple myeloma who presented with stridor due to a mass involving the larynx which was initially proven to be plasmacytoma on biopsy. She had evidence of multiple myeloma of IgA la...
متن کاملConcurrent atrioventricular block, sinus arrest and pneumothorax in a dog secondary to vehicle accident
In human several kinds of electrocardiographic findings have been reported in association with pneumothorax such as decreased and/or alternating QRS amplitude (electrical alternans). However, electrocardiographic changes concurrent with pneumothorax have rarely been discussed in veterinary literature. A 3-year-old male crossbreed dog was presented with a history of car accident. Thoracic au...
متن کاملTwo Secondary Primary Malignancies after Bortezomib Therapy for Multiple Myeloma: A Single-center Experience
Multiple myeloma (MM) is the second most common hematological malignancy. The introduction of novel agents such as thalidomide, bortezomib, and lenalidomide in more recent years has significantly improved the response rate, progression‐free survival (PFS), and overall survival (OS) of MM patients.[1,2] However, alongside these benefits, a significant increased risk of developing secondary prima...
متن کاملCounterpoint: Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma.
Multiagent induction chemotherapy leads to high response rates in multiple myeloma. The phase III Southwest Oncology Group trial involving 525 patients established lenalidomide, bortezomib, and dexamethasone (RVD) as a preferred induction regimen; in this trial, RVD demonstrated an overall response rate of 81.5%, with 15.7% of responses complete responses (CR), and 27.8% very good partial respo...
متن کامل